Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (November 2023)
30 slides from Maat Pharma's investor presentation, November 2023
Slide 1: Enhancing Survival through Microbiome Innovation
v7 » | Enhancing Survival through Microbionte ry fe Y. * Innovation ° 2 sears MaaT Pharma
Slide 2: Disclaimer
MaaT Pharma Disclaimer This document has been prepared by Maa Pharma (the “Company*) andis for informationandbackgroundpurposesonly. While the information contained herein has been preparedin good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors g
Slide 3: A late-stage clinical biotech leading microbiome therapies in oncology
MaaT Pharma November 23 03 . ss . . . . . _ MaaT Pharma: A late-stage clinical biotech, leading the way in Microbiome therapies in oncology la > A LEADER Listed on Euronext (MAAT.PA) global leader in the development of Microbiome Ecosystem Therapies \ in oncology to enhance patient survival ZG Found
Slide 4: Host-Microbiota Interactions are Critical for a Functional Immune System
MaaT Pharma Host - Microbiota Interactions are Critical for a Functional Immune System A rich and diversified gut ecosystem actively modulates the immune system functionality 01 A diversified microbiome contributes to the education and modulation of our immune system throughout life Bacterial richne
Slide 5: Low High Intermediate
1,00 0,75 0,50 * * 0,25 0,00 0 200 400 600 Low High Intermediate
Slide 6: A Step-by-Step Increasing Value Creation Strategy
MaaT Pharma, A Step-by-Step Increasing Value Creation Strategy Backed by Leading Capabilities in Microbiome Drug Candidate Production Zant a XZ Drrint Driving near-term value Progressing next-generation with the donor-derived MET-N platform co-cultured scalable MET-C platform MaaTO13 © MaeT034 © Maa
Slide 7: Research Engine Powered by Metagenomics and Al-driven Candidate Selections
MaaT Pharma November 23 o7 Cutting-edge Research Engine Powered by Metagenomics x and Al-driven Candidate Selections Va ( DATA >) in Healthy Selected Native Therapeutics donors MET-N XR / ~Y . ‘Op i Leading discovery and Al-driven platform tC - Leading Platform AI ENGINE Seige Y{ pata} poiebome for
Slide 8: A robust pipeline of late and early assets
MaaT Pharma, A robust pipeline of late and early assets November 23 08 Platform Program Indication Preclinical Phase! Phase ll Phase lll Upcoming milestone MaaT013 4 1O PoC Melanoma > Results H2.24/ H1.25 MET-N <4 HSCT ODD EMA > Safety Interim H2.24 MaaTo33. << ALS |ASO ° Results H1.24 MaaT034. > lo
Slide 9: Driving near-term value with the donor-derived MET-N platform
Driving near-term value with the donor- derived MET-N platform MET-N
Slide 10: Microbiome Restoration with MaaT013: A Maximum-Density Product
MaaT Pharma, 10 Microbiome Restoration with MaaT0O13: A Maximum-Density Product * for Fast Engraftment in Acute Situations C > Characteristics GE Administration Available Clinical Data + Curative approach PP Efficacy evaluation in EAP + MaaT013 has received Orphan Drug Designation from FDA and EMA +
Slide 11: MaaT013 Aims to Enhance Survival in Steroid & Ruxolitinib Resistant aGVHD
November 23 1 MaaT013 Aims to Enhance Survival in Patients with Steroid & Ruxolitinib ‘ Resistant aGVHD through Gut Microbiota Restoration Intestinal dysbiosis is associated with higher mortality in hemato-oncology ! Chemotherapy Antibiotics > Irradiation > Immunosuppressors 50% cee Allogenic Hemato
Slide 12: ARES, a pivotal Phase 3 trial to treat aGVHD in 3rd line
MaaT Pharma November 23 12 ARES, a pivotal Phase 8 trial to treat AGVHD in 3" line showing ~ ARES “high efficacy and low toxicity” as concluded by the DSMB ea Treatment Period D1, 5, 10 Patients > Screening a Gi GF ss with SR-Gl-aGvHD (D4 to D4) MaaT013 administration 4th dose if relapse after respo
Slide 13: Early Access Program confirms impact on survival
Early Access Program (EAP) confirms impact on survival ‘ when primary endpoint is achieved ir Global EAP populations GILORR Overall Survival Rate Responders vs. Non responders Patients (%) 100 rood 6mo y2mo 69% 50. 59% 50. 28% 14% — 4, GI-ORR 0. = cr iComplete Response) ° 100 200 300 400 = verre 7 =
Slide 14: MaaT033 - The oral ecosystem microbiome capsule
Ensuring Optimal Microbiota Function: MaaTO33 - The oral ecosystem microbiome capsule for adjunctive and maintenance therapy Pooled microbiota: high-richness, high-diversity, full ecosystem, Characteristics Microbiome Ecosystem Therapy containing Butycore® Administration Oral (a lyophilized capsule)
Slide 15: MaaT033 to ensure optimal gut microbiota in patients receiving allo-HSCT
MaaTO33 to ensure optimal gut microbiota to improve survival in patients ‘ receiving allo-HSCT Intestinal dysbiosis is associated with higher mortality in hemato-oncology ! = far] e Chemotherapy Antibiotics United States EU5 Japan — Allogenic Hematopoietic > Irradiation Stem Cell Transplantation > I
Slide 16: Phase 2b PHOEBUS designed to establish MaaT033 as adjunctive treatment
November 23 16 Phase 2b PHOEBUS designed to establish MaaTO33 as an adjunctive & * treatment for patients receiving allo-HSCT 387 patients ina Primary endpoint: of MaaT033 in study Atleast targeted globally Study started in , results are expected in 18-2idays Neutrophilrecovery patients dosed pre- P
Slide 17: MaaT033 to slow down Amyotrophic Lateral Sclerosis progression
MaaT Pharma, November 23 MaaT0O33 to slow down Amyotrophic Lateral Sclerosis progression Amyotrophic Lateral Sclerosis > Could affect up to 60,000 patients in US & EU by 20401 > Paralysis and death 3 to 5 years after diagnostic? > Currently no curative treatment and few symptomatic treatments > Upto
Slide 18: Progressing next-generation co-cultured donor independent scalable MET-C platform
Progressing next- generation co-cultured donor independent scalable MET-C platform MET-C
Slide 19: MET-C product generation driven by predictive Al and proprietary validation
November 23 19 MET-C product generation is driven by predictive Al and by state-of-the-art x proprietary in vitro and in vivo validation In silico Data Clinical & host parameters data Drug discovery Donor independent ecosystem candidate Invitro soreening Drug development In vivo model Indication-spe
Slide 20: Boosting Cancer Therapy: MaaT034 Synthetic Microbiota
November 23 20 Boosting Cancer Therapy: MaaT034 - Ground-breaking, Donor-Independent, Full ~* Ecosystem Synthetic Microbiota to Optimize Immune Checkpoint Inhibitor Treatment C > Characteristics (© 02 Administration Development Program First clinical batches manufactured expected in H2.2024 First in
Slide 21: A diverse gut microbiome increases survival in patients receiving ICI
4a MaaT Pharma, November 23 A diverse gut microbiome increases survival in patients receiving Immune Checkpoint Inhibitors (ICI) 2i Higher microbiome richness —> better response rate to ICI in patients with metastatic melanoma Proportion surviving Progression-free — High — Intermediate 1.0 — Low 0.5
Slide 22: Proof of concept study with MaaT013 to improve ICI response
Proof of concept study with MaaT013 to improve ICI response r yor >) : - as Relative @ ¢) MaeT0ls PICASSO RCT desi Le (©) High abunde lesign ©) bow ©) ta Faecalibacterium Bifidobacterium | Suncanee \ High Total follow-up 51 weeks -28 to-2 from DO Blind Period Open Period Medium ® High (@) Medium @)
Slide 23: Envisioning the Future: MaaT03X
OY MaaT Pharma, November 23 23 Envisioning the Future: MaaTO3X —Tailor-made Al-driven Super-Competent x Synthetic Microbiota for specific indications _ High richness, co-cultured, Characteristics Super-competent full ecosystem microbiome a . Oral Administration \ hilized f (a lyophilized capsule) Mu
Slide 24: End-to-End in-house cGMP manufacturing
End-to-End in-house cGMP manufacturing All MET
Slide 25: Building Europe's largest specialized cGMP manufacturing facility
Building Europe’s * largest specialized cGMP manufacturing facility for Microbiome Ecosystem Therapies Building a dedicated 1,600m2 site (expandable) to support demands until 2034 for MET-N clinical and future commercial production, R&D, and clinical batches of MET-C products (MaaT034 & MaaT3X famil
Slide 26: Key Takeaways
Key Takeaways
Slide 27: Meaningful milestones in both the near and long term
MaaT Pharma, Meaningful milestones in both the near and long term 2023 MaaT013 (pooled enema) GvHD | ARES P3 G-LORR mid-24 IO Mela. | PICASSO P2a Results H2.24/H1.25 2025 2026 + GD) 27 MaaT013 (pooled enema) GvHD | Final Results (OS) GvHD | Commercial launch MaaT0O83 (pooled capsule) HSCT | PHOEBUS
Slide 28: A Step-by-Step Increasing Value Creation Strategy
MaaT Pharma, A Step-by-Step Increasing Value Creation Strategy Backed by Leading Capabilities in Microbiome Drug-Candidate Production November 23 MET-N MET-C MaaT03X MaaT034 oo MaaT033 CH MaaT013 & Ad bi P. tents ° © Co-cultured caps. Co-cultured capsule atients Pooled enema Pooled capsule Synthetic
Slide 29: Corporate Social Responsibility
MaaT Pharma, Corporate Social x Responsibility MaaT Pharma aims to become the source of Microbiome excellence providing patients with safe and innovative medicines. The Company develops products from sustainable biological matters, driving optimal impact of Microbiome. @ g" DEVELOPMENT na GOALS = wa
Slide 30: Thank you
Thank you [email protected]